Researcher
Daan Dierickx
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Hematology (Division)
Responsible
From1 Oct 2019 → Today - Laboratory of Experimental Hematology (Division)
Member
From1 Oct 2013 → Today
Projects
1 - 10 of 14
- Molecular characterization of hyperactive T cell receptor signaling in peripheral T cell lymphoma to uncover druggable targetsFrom2 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Molecular characterization of genetic events driving development of peripheral T cell lymphomaFrom2 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- GAINING INSIGHT IN THE MUTATIONAL PROFILE OF PT-DLBCL AND ASSESSING ITS BIOLOGICAL EFFECTS AND TRANSFORMING POTENTIALFrom2 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Degradation of CDK1 and HDACs as a strategy to treat T-cell malignanciesFrom1 Oct 2023 → TodayFunding: BOF - projects
- Characterization of non-canonical EZH2 transcriptional complexes to identify new therapeutic targets in peripheral T cell lymphoma.From1 Sep 2023 → TodayFunding: Other federal public and semi-governmental institutions
- Molecular characterization of genetic events driving development of peripheral T cell lymphomaFrom1 Jan 2023 → TodayFunding: FWO research project (including WEAVE projects)
- Molecular characterization of hyperactive T cell receptor signaling in peripheral T cell lymphoma to uncover druggable targetsFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Viral Oncology: molecular biology and pathogenesis of post-transplant lymphoproliferative disorder (PTLD)From13 Sep 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Extensive preclinical validation of combinations of targeted treatment for peripheral T cell lymphomaFrom10 Aug 2021 → 30 Sep 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- Development and validation of a novel platform for fast and easy diagnosis of von Willebrand diseaseFrom1 Jan 2021 → 31 Dec 2022Funding: IOF - technology validation in lab
Publications
31 - 40 of 203
- Maternal and neonatal outcomes in 80 patients diagnosed with non-Hodgkin lymphoma during pregnancy: results from the International Network of Cancer, Infertility and Pregnancy(2021)
Authors: Charlotte Maggen, Daan Dierickx, Kristel Van Calsteren, Frédéric Amant
Pages: 52 - 62 - Optimization of the detection of inhibitory autoantibodies against the VWF-cleaving protease ADAMTS13 with an automated chemiluminescent ADAMTS13 activity immunoassay(2021)
Authors: Marc Jacquemin, Kathelijne Peerlinck, Daan Dierickx
Pages: 290 - 297 - Prognostic superiority of International Prognostic Index over [18F]FDG PET/CT volumetric parameters in post-transplant lymphoproliferative disorder(2021)
Authors: Daan Dierickx, Vibeke Vergote, Christophe Deroose
- Real-world data confirming the efficacy and safety of decitabine in acute myeloid leukaemia - results from a retrospective Belgian registry study(2021)
Authors: Daan Dierickx
Pages: 98 - 105 - Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies(2021)
Authors: Laurent Godinas, Yannick Van Herck, Natalie Lorent, Daan Dierickx, Geert Meyfroidt, Lore Vanderbeke, Valentijn Vergote, Katrien Lagrou, Peter Verhamme, Joost Wauters, et al.
Pages: 1100 - 1105 - Quantitative Whole-Body Diffusion-weighted MRI after One Treatment Cycle for Aggressive Non-Hodgkin Lymphoma Is an Independent Prognostic Factor of Outcome(2021)
Authors: Oliver Bechter, Daan Dierickx, Ann Janssens, Gregor Verhoef, Raymond Oyen, Michel Koole, Vincent Vandecaveye
- Inflammatory aortitis in a patient with type 2 hyper IgM syndrome(2021)
Authors: Frederik Staels, Thomas Tousseyn, Daan Dierickx, Stephanie Humblet-Baron, Adrian Liston, Steven Vanderschueren, Rik Schrijvers
Pages: E87 - E89 - A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol(2021)
Authors: Ellen De Langhe, Daan Dierickx
- Semi-Quantitative Characterization of Post-Transplant Lymphoproliferative Disorder Morphological Subtypes with [18F]FDG PET/CT(2021)
Authors: Vibeke Vergote, Daan Dierickx, Thomas Tousseyn, Christophe Deroose
- Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter phase II HOVON trial(2020)
Authors: Daan Dierickx
Pages: 2805 - 2812